|
Volumn 50, Issue 6, 2011, Pages 1033-1044
|
Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CD20 ANTIGEN;
IMMUNOLOGIC FACTOR;
MONOCLONAL ANTIBODY;
RITUXIMAB;
SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;
ANIMAL;
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY;
ARTICLE;
B LYMPHOCYTE;
BINDING SITE;
CELL CULTURE;
COMPARATIVE STUDY;
DISEASE MODEL;
DRUG EFFECT;
HUMAN;
IMMUNOLOGY;
IN VITRO STUDY;
MACACA FASCICULARIS;
METABOLISM;
RANDOMIZATION;
SENSITIVITY AND SPECIFICITY;
STATISTICAL MODEL;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
ANTIBODY-DEPENDENT CELL CYTOTOXICITY;
ANTIGENS, CD20;
B-LYMPHOCYTES;
BINDING SITES;
CELLS, CULTURED;
DISEASE MODELS, ANIMAL;
HUMANS;
IMMUNOLOGIC FACTORS;
LINEAR MODELS;
MACACA FASCICULARIS;
RANDOM ALLOCATION;
SENSITIVITY AND SPECIFICITY;
SINGLE-CHAIN ANTIBODIES;
|
EID: 84863965582
PISSN: None
EISSN: 14620332
Source Type: Journal
DOI: 10.1093/rheumatology/keq423 Document Type: Article |
Times cited : (9)
|
References (0)
|